National Brain Tumor Society’s
2016 Scientific Summit

District Hall, 75 Northern Avenue, Boston, MA
September 29, 2016, 8:15 AM – 5:00 PM

Leveraging the Inflection Point in Cancer Research to Advance Brain Tumor Treatments

This incredible, interactive day brings together renowned leaders from all aspects of the brain tumor field — many actively engaged in our ground-breaking research initiatives —  to share progress, explore emerging opportunities, and build strong and diverse partnerships to fast-track new discoveries toward a cure.

The day features opportunities for robust and open dialog between participants and top experts from across the brain tumor community.

8:15 AM – 9:00 AM
Welcome
Michael Nathanson, JD – Chair, National Brain Tumor Society Board of Directors

Keynote
Outcomes of the Cancer Moonshot: Moving from Inflection to Further Progress  Dr. Elizabeth Jaffee – Cancer Moonshot Blue Ribbon Panel Co-Chair, Johns Hopkins University School of Medicine

9:00 AM – 12:05 PM
NBTS Research Perspective:
THEME: COLLABORATION — What’s Working to Accelerate Progress and Capitalize on the Inflection Point in Cancer Research
(Q&A built in to individual time slots)
Introduction, Moderator: Dr. WK Alfred Yung

Together we will explore ways to overcome barriers; talk about successful, ongoing collaborative efforts; and learn more about exciting upcoming collaborations in the field, as well as how to optimize a “team science” approach to brain tumor research.

  • Defeat GBM: Progress — Dr. Frank Funari, Dr. John de Groot
    + Discussion Panel — Dr. Paul Mischel, Dr. Ingo Mellinghoff, Dr. Tim Cloughesy, Dr. Erik Sulman
  • GBM AGILE (An Adaptive, Global, Innovative Learning Environment) — Unprecedented International Clinical Trial in GBM — Dr. Tim Cloughesy

BREAK

  • Project Impact: Defeat Pediatric Brain Tumors — Poised to Start — Dr. Roger Packer and Dr. Nada Jabado
  • The Glioma Longitudinal AnalySiS (GLASS) Consortium — Dr. Roel Verhaak
  • The Importance of Patient Registries – Highlighting the International Low-Grade Glioma Registry — Dr. Elizabeth Claus

PICK UP BOX LUNCHES OUTSIDE
12:30 PM – 1:10 PM
LUNCHTIME SESSION — Real World Evidence for Drug Development
(Q&A built in)

Welcome and Introduction: David Arons
Dr. Joohee Sul, FDA

Lunch session will highlight how drug development has become more patient focused and how  advances and opportunities in use of real-world patient data — gathered from a number of sources including health information technology platforms — can be used to supplement or support regulatory decisions in the drug approval process.

1:15 PM – 3:25 PM
THEME: Innovation Today & Tomorrow — The Hot Topics/Emerging Opportunities in Brain Tumor Research
(Q&A built in to individual time slots)

Welcome: Dr. Susan Pannullo
Introduction, Moderator: Dr. WK Alfred Yung

Every day we are seeing exciting, new, innovative approaches emerging to combat the range of challenges we face in our field. Together we will explore a variety of forms this innovation is taking — including clinical trials, advancements in technology, cutting-edge areas of research, and new treatment protocols — and where it should go next according to the unique perspectives of our diverse participants.

  • World Health Organization (WHO) Brain Tumor Re-classification Update & Impact — Dr. Maria Martinez-Lage
  • Advances in Treatment Development Landscape — Dr. Tim Cloughesy
  • Development of Imaging Biomarkers as Surrogate Endpoints — Dr. Dan Barboriak
  • Liquid Biopsy for Brain Tumors — Dr. Ingo Mellinghoff
  • Epigenetics: A Rapidly Emerging Class of Therapeutic Targets for Brain Tumors (children & adult) — Dr. Paul Mischel

BREAK
3:35 PM – 4:50 PM
Panel & Open Discussion
THEME: What Progress Should we Demand to see in the Next 1-3 Years?

Moderator: Dr. Robert Strausberg, with co-moderators Dr. WK Alfred Yung and David Arons
Panelists include: Dr. Joohee Sul, Dr. Patrick Wen, Dr. Andrew Joe, Ashley Dabbiere, Allison Bishoff

This interactive session is set to discuss where we need to be heading next in adult and pediatric brain tumor research, patient engagement/patient role, treatment, policy, and advocacy. Join in the robust conversation from multiple perspectives regarding what needs to be leveraged or changed in order to make real progress in the fight against brain tumors and what we each have to do going forward.

  • Welcome Opening Statement and Key Questions for Discussion
  • Robust Panel and Audience Engagement
  • Summary and Wrap-up

4:50 PM – 5:00 PM
Closing Remarks
David Arons, CEO, National Brain Tumor Society


Registration is now closed. For more information contact Amanda Bates at abates@braintumor.org or 516-632-8880.